Literature DB >> 10588295

Sample-size calculation for a log-transformed outcome measure.

R Wolfe1, J B Carlin.   

Abstract

The outcome measure of interest in clinical trials sometimes requires transformation to the logarithmic scale for analysis. This paper examines sample-size calculation for both independent groups and matched-pairs trials for log-transformed outcomes. For both types of trial, we demonstrate how the calculation can be formulated in terms of a relative treatment effect and a statement of relative variability, both specified on the original scale of measurement. For a comparison of two independent groups, the relative treatment effect is the ratio of group geometric means (or alternatively, group arithmetic means) and the coefficient of variation is used as a summary of relative variability. For a matched-pairs comparison, the appropriate relative treatment effect is the geometric mean of the within-pair ratios, and relative variability can be specified as an upper bound on within-pair ratios under a null hypothesis of the relative effect being equal to 1 (i.e., no difference). We discuss the clinical study that motivated this work and demonstrate the application of the sample-size calculation to this study.

Mesh:

Substances:

Year:  1999        PMID: 10588295     DOI: 10.1016/s0197-2456(99)00032-x

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  13 in total

1.  Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients.

Authors:  Leonardo Calza; Laura Mosca; Daria Pocaterra; Benedetta Piergentili; Vincenzo Colangeli; Roberto Manfredi; Annalisa Erario; Gabriele Grossi; Gabriella Verucchi; Pierluigi Viale
Journal:  Eur J Clin Pharmacol       Date:  2010-09-28       Impact factor: 2.953

2.  Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial.

Authors:  Pietro Ravani; Alberto Magnasco; Alberto Edefonti; Luisa Murer; Rossella Rossi; Luciana Ghio; Elisa Benetti; Floriana Scozzola; Andrea Pasini; Nadia Dallera; Felice Sica; Mirco Belingheri; Francesco Scolari; Gian Marco Ghiggeri
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-12       Impact factor: 8.237

3.  Sample size determination for logistic regression on a logit-normal distribution.

Authors:  Seongho Kim; Elisabeth Heath; Lance Heilbrun
Journal:  Stat Methods Med Res       Date:  2015-03-04       Impact factor: 3.021

4.  Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial.

Authors:  Pietro Ravani; Roberta Rossi; Alice Bonanni; Robert R Quinn; Felice Sica; Monica Bodria; Andrea Pasini; Giovanni Montini; Alberto Edefonti; Mirco Belingheri; Donatella De Giovanni; Giancarlo Barbano; Ludovica Degl'Innocenti; Francesco Scolari; Luisa Murer; Jochen Reiser; Alessia Fornoni; Gian Marco Ghiggeri
Journal:  J Am Soc Nephrol       Date:  2015-01-15       Impact factor: 10.121

5.  Parent initiated prednisolone for acute asthma in children of school age: randomised controlled crossover trial.

Authors:  P J Vuillermin; C F Robertson; J B Carlin; S L Brennan; M I Biscan; M South
Journal:  BMJ       Date:  2010-03-01

6.  Reproducibility of color Doppler imaging.

Authors:  Ingeborg Stalmans; Brent Siesky; Thierry Zeyen; Steffen Fieuws; Alon Harris
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-11       Impact factor: 3.117

7.  Rituximab in children with resistant idiopathic nephrotic syndrome.

Authors:  Alberto Magnasco; Pietro Ravani; Alberto Edefonti; Luisa Murer; Luciana Ghio; Mirco Belingheri; Elisa Benetti; Corrado Murtas; Giovanni Messina; Laura Massella; Maria Gabriella Porcellini; Michela Montagna; Mario Regazzi; Francesco Scolari; Gian Marco Ghiggeri
Journal:  J Am Soc Nephrol       Date:  2012-05-10       Impact factor: 10.121

8.  Sample size requirements for studies of treatment effects on beta-cell function in newly diagnosed type 1 diabetes.

Authors:  John M Lachin; Paula L McGee; Carla J Greenbaum; Jerry Palmer; Mark D Pescovitz; Peter Gottlieb; Jay Skyler
Journal:  PLoS One       Date:  2011-11-10       Impact factor: 3.240

9.  Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.

Authors:  Alberto M Borobia; Antonio J Carcas; Mayte Pérez-Olmeda; Luis Castaño; María Jesús Bertran; Javier García-Pérez; Magdalena Campins; Antonio Portolés; María González-Pérez; María Teresa García Morales; Eunate Arana-Arri; Marta Aldea; Francisco Díez-Fuertes; Inmaculada Fuentes; Ana Ascaso; David Lora; Natale Imaz-Ayo; Lourdes E Barón-Mira; Antonia Agustí; Carla Pérez-Ingidua; Agustín Gómez de la Cámara; José Ramón Arribas; Jordi Ochando; José Alcamí; Cristóbal Belda-Iniesta; Jesús Frías
Journal:  Lancet       Date:  2021-06-25       Impact factor: 79.321

10.  A robustness study of parametric and non-parametric tests in model-based multifactor dimensionality reduction for epistasis detection.

Authors:  Jestinah M Mahachie John; François Van Lishout; Elena S Gusareva; Kristel Van Steen
Journal:  BioData Min       Date:  2013-04-25       Impact factor: 2.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.